Verastem Inc., of Boston, priced an offering of 5 percent convertible senior notes due 2048 through a registered direct offering. The aggregate principal amount is $150 million. Net proceeds will total about $145.4 million and will be used for continued development of recently approved Copiktra (duvelisib) and other candidates, with the balance to fund working capital, capital expenditures and other general corporate purposes. Lazard Frères & Co. LLC acted as placement agent. (See BioWorld, Sept. 26, 2018.)